METASTATIC MELANOMA

This study tested a drug called ibrutinib in 18 people with stage IV melanoma that had not responded to previous treatments. Ibrutinib works by blocking certain enzymes that help cancer cells grow. The main goal was to see if the drug could shrink tumors, and researchers also loo…

This early-phase trial tests the safety and best dose of combining two drugs—ziv-aflibercept and pembrolizumab—in people with advanced solid tumors that have spread. Ziv-aflibercept cuts off the tumor's blood supply, while pembrolizumab helps the immune system fight cancer. The s…

This study tests a combination of three drugs (dabrafenib, trametinib, and navitoclax) in people with BRAF-mutant melanoma or other solid tumors that have spread or cannot be removed by surgery. The goal is to find the best dose and see how well the drugs shrink tumors. About 75 …

This study tests whether adding an experimental drug (tazemetostat) to the usual two-drug therapy (dabrafenib and trametinib) can help people with advanced melanoma whose cancer has stopped responding to standard treatment. About 16 adults with a specific gene mutation (BRAF V600…

This early-phase trial tests the safety and best dose of sonidegib combined with the immunotherapy pembrolizumab in people with advanced solid tumors that have spread. The goal is to see if this drug pair can shrink tumors or slow their growth. About 36 adults with cancers like m…

This study tests whether combining three drugs—an immunotherapy (nivolumab) with two targeted therapies—can shrink or control advanced melanoma that has spread or can't be removed. It includes people with a specific gene mutation (BRAF V600) whose cancer got worse after prior tre…

This study tests whether adding an experimental drug (GSK2636771) to an approved immunotherapy (pembrolizumab) can help control metastatic melanoma in patients whose tumors have a specific genetic change (PTEN loss). About 27 adults with advanced melanoma that didn't respond to p…

This early-phase study tests a personalized vaccine (NeoVax) combined with CDX-301 and standard immunotherapies (nivolumab or pembrolizumab) in 10 people with advanced melanoma. The goal is to find the safest dose and see if the vaccine boosts the immune system's attack on cancer…

This study tested a combination of three drugs—pembrolizumab, trametinib, and dabrafenib—given for a short time to people with advanced melanoma that cannot be removed by surgery. The goal was to see if this shorter treatment could shrink or control tumors while allowing patients…

This study tested whether adding a drug called GM-CSF (sargramostim) to the immunotherapy ipilimumab helps people with advanced melanoma that cannot be surgically removed. About 245 participants were randomly assigned to receive ipilimumab alone or with GM-CSF. The main goal was …

This study tests a new combination of three treatments—an immune-boosting injection (IL-2), targeted radiation, and the immunotherapy drug pembrolizumab—in adults with advanced lung, skin, kidney, or head and neck cancers that no longer respond to standard immunotherapy. The goal…

This study is for people with advanced melanoma that cannot be removed by surgery. It tests a flexible approach to giving two immunotherapy drugs (ipilimumab and nivolumab). Instead of always giving four doses, doctors will check after two doses. If the tumor is shrinking, no mor…

This early-phase study tests a combination of two drugs—pembrolizumab (an immunotherapy that helps the immune system fight cancer) and ibrutinib (which blocks certain enzymes that help cancer grow)—in people with advanced melanoma that cannot be surgically removed. The main goals…

This study tests whether using heat (thermal ablation) followed by very precise radiation (stereotactic radiosurgery) can better control cancer that has spread to the spine and is pressing on the spinal cord. About 60 adults with various solid tumors (like lung, breast, or prosta…

This study tests a new drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The goal is to find a safe dose and see if the drug can shrink tumors. About 125 adults with cancers like glioblastoma, melanoma, breast, or prostate ca…

This early-stage study tests a new approach for people with advanced melanoma that has not responded to standard treatments. Nine participants will receive a special virus (TILT-123) designed to boost the immune system, along with chemotherapy and their own lab-grown immune cells…

This phase III trial tested two different sequences of drugs in 267 people with advanced melanoma that has a BRAF mutation and cannot be removed by surgery. One group started with immunotherapy (ipilimumab and nivolumab) followed by targeted therapy (dabrafenib and trametinib), w…

This early study tests a treatment called lifileucel (LN-144) for people with melanoma that has spread to the brain and stopped responding to standard immunotherapy. The treatment uses a patient's own immune cells, grown in a lab, to attack the cancer. The study aims to see if th…

This study tests whether adding a drug called rigosertib to the immunotherapy pembrolizumab can help shrink or control advanced melanoma that has stopped responding to standard immunotherapy. About 7 adults with melanoma that cannot be surgically removed or has spread will receiv…

This early-phase study tested a combination of two drugs, cediranib and selumetinib, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could block tumor growth by cutting off blood…

This early-stage study tests a combination of drugs (tacrolimus, nivolumab, and ipilimumab) in 12 kidney transplant recipients who have advanced skin cancers that cannot be surgically removed. The goal is to see if this treatment can shrink or control the cancer while keeping the…

This early-stage trial aimed to test the safety and effectiveness of STIL101, a personalized cell therapy made from a patient's own tumor-fighting T cells, for several advanced cancers including pancreatic, colorectal, kidney, cervical, and melanoma. The treatment involved collec…

This study tests an experimental therapy called lifileucel, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced melanoma that has not responded to standard treatments. About 100 adults with unresectable or metastatic melanoma will receive this on…

This study tests whether adding infliximab (a drug used for arthritis) to standard immunotherapy can reduce serious side effects while still treating advanced melanoma. About 36 adults with stage 3 or 4 melanoma who haven't had prior treatment will receive either immunotherapy al…

This study tests whether adding tocilizumab to standard immunotherapy (ipilimumab and nivolumab) can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive the combination to see if it is safer and still eff…

This study looks at whether a focused, one-time radiation treatment called stereotactic radiosurgery (SRS) can control melanoma that has spread to more than 3 spots in the brain, while also protecting memory and thinking skills. About 49 adults with advanced melanoma and multiple…

This study was designed to test a device called NovoTTF-200A combined with the immunotherapy drug pembrolizumab in people with melanoma that had spread to the brain. The goal was to see if the combination was safe and effective. However, the study was withdrawn before any partici…

This study tests whether combining two or three drugs can shrink or control melanoma that has spread to the brain. The drugs work by blocking tumor growth and helping the immune system attack cancer cells. The trial involves 29 adults with untreated brain metastases and aims to s…

This study compares two treatments for metastatic melanoma that has spread: high-dose immunotherapy (IL-2) alone versus the same immunotherapy plus targeted radiation (SBRT). The goal is to see if adding radiation helps shrink tumors better. 44 adults with up to 3 tumors that can…

This study tests an inhaled form of a protein called interleukin-2 (IL-2) to treat cancers that have spread to the lungs, such as melanoma, kidney cancer, and sarcoma. The goal is to find the safest dose and see if it can shrink tumors. About 70 adults with advanced cancer and lu…

This early-phase study tests a new treatment called OBX-115, which uses a patient's own tumor-fighting immune cells that have been modified in the lab to include a protein (IL15) to help them survive longer. These cells are given along with acetazolamide to adults with metastatic…

This early-phase study tests whether a mix of drugs and targeted radiation can help the immune system recognize and attack hard-to-treat solid tumors. About 14 adults with advanced melanoma, breast cancer, or other solid cancers that cannot be surgically removed will receive inje…

This early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…

This early-phase study tests a new way to fight advanced melanoma. Doctors take a patient's own immune cells (T-cells), modify them in a lab to resist a tumor-blocking signal (TGF-beta), and return them to the body along with a drug (IL-2) that boosts their activity. The goal is …

This early-stage study tests a new drug, RO7247669, that works like a double-pronged key to help the immune system attack cancer cells. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options will r…

This study looks at whether eating a high-fiber diet can change the gut bacteria in people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a period of time. The m…